TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05249959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C))
Description: Standard Induction phase (cycle 1-2 of R-BAC every 28 days according to the following schedule):~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2-4~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C)
Description: Reduced Induction phase (cycle 1-2 with two different schedules for patients deemed FRAIL or UNFIT for standard induction therapy,based on protocol dose and as per medical judgment are allowed).~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 70 mg/m2, Days 2 and 3~* Cytarabine 500 mg/m2, Day 2 and 3~or~* Rituximab 375 mg/m2 i.v. Day 1~* Bendamustine 100 mg, Days 2 and 3~* Cytarabine 500 mg, Day 2 and 3~After restaging at the End of Induction (EOI) patients with CR (complete response), PR (partial response) or SD (stable disease) will receive:~CONSOLIDATION PHASE:~* 2 infusions of loncastuximab tesirine at a dose of 150 microgram/kg every three weeks followed by~* 2 infusions of loncastuximab tesirine at a dose of 75 microgram/kg every three weeks
Study: NCT04339036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine Oral Product
Description: Capecitabine 750 mg/m2 twice daily orally for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide Oral Product
Description: temozolomide 200 mg/m2 orally on Days 10-14, with 14 days between cycles

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: transarterial radioembolization
Description: Trans-arterial radioembolization (TARE) on Day 7 of cycle 2 and, if needed for the other lobe, Day 7 of either cycle 3 or 4.
Study: NCT06236061

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ
Description: LCZ 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ/AML 200 mg/2.5 mg
Description: LCZ/AML 200 mg/2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ/AML 200 mg/5 mg
Description: LCZ/AML 200 mg/5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ/AML 200 mg/10 mg
Description: LCZ/AML 200 mg/10 mg
Study: NCT06188741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib (KoselugoTM) at the FDA approved dose of 25 mg/m2/dose PO BID
Study: NCT04977024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Vaccine
Description: Receive SOC mRNA SARS-CoV-2 vaccine IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Description: Given IM
Study: NCT05979922

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Coping
Description: Participants will receive the Caring Mind mobile app containing the Mindfulness-based Cognitive Coping program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Educational/Resources Program
Description: Participants will receive a traditional educational/resources program, containing a downloadable workbook and online resources.
Study: NCT05028582

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ARQ-154 Vehicle
Description: Vehicle
Study: NCT04956601

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: vaginal brachytherapy/pelvic external beam radiotherapy
Description: high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: vaginal brachytherapy/pelvic external beam radiotherapy
Description: high-dose-rate vaginal brachytherapy; pelvic external beam radiotherapy
Study: NCT06549452

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Intervention
Description: Our HIPPA-compliant texting platform is linked to the Fitabase Interface. Real time activity data are transmitted from the participant's smartphone to Fitabase via cellular network. Participants will receive 3-5 texts/day in sync with their preferred schedule defined at enrollment and taking into account school schedules as relevant. These texts use personal, disease-specific, and provider information to deliver two types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.

Intervention type: DEVICE
Group type: OTHER
Intervention: Usual Care
Description: Routine medical care
Study: NCT06568055

Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.

Intervention type: OTHER
Intervention: No Intervention
Description: This is non-interventional study.
Study: NCT03733262

Intervention type: OTHER
Intervention: De-prescribing Trial
Description: Validated de-prescribing algorithms will be applied for any patients identified as taking one of the 9 study drugs in order to determine whether or not physician should consider a deprescribing trial. If they are are identified as candidates for deprescribing and consent to participate in the trial, they will enter the Deprescribing Trial group and begin the deprescribing trial.
Study: NCT05184595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib delivered in OH only
Description: Patients receive the whole treatment en OH.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carfilzomib delivered in OH and HaH combined
Description: Patients receive the first cycle of treatment in OH. Then, they are randomized between exclusive OH treatment and combined treatment in OH and at home with HaH services.
Study: NCT06027229

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2372
Description: Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVX-CoV2372
Description: Novavax COVID-19 Vaccine Booster for Omicron XBB.1.5
Study: NCT05072340

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilience Skills Enhancement (RISE)
Description: The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton \& Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience Skills Enhancement (RISE)
Description: The RISE training was developed according to theory, empirical evidence and contextual information. The contents, components, pedagogy, and technical elements of RISE is established based on the resilience theory (Szanton \& Gill, 2010) systematic review and meta-analysis, meta-synthesis, and qualitative study (Ang et al., 2021). Ethical and quality standards was assessed using the Health on the Net code of conduct and the Health-Related Website Evaluation Form respectively. The overall rating of the designed RISE is more than 75% of the total possible points to ensure quality of website by three research team members.
Study: NCT06287671

Intervention type: PROCEDURE
Intervention: Colorectal resection or stoma closure
Description: Elective open or minimally invasive resection for colorectal cancer, IBD or other benign colorectal disorder, or stoma closure
Study: NCT05906615

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine IV
Description: Administration of IV lidocaine will take place according to the standard protocol as is currently already used in daily clinical practice. First, a lidocaine bolus of 1.5mg/kg is administered, followed by a continuous infusion of 1.5mg/kg/hour. When no pain relief is noticed, each 15 minutes the dose is raised with 1ml up to a maximum of 2mg/kg/hour. If again no pain relief is noticed, the anesthesiologist is consulted. When the anesthesiologist agrees, and no side effects occur, lidocaine infusion can be increased up to a maximum of 2.5mg/kg/hour, with a maximum of 250mg/hour. When there is a pain response - pain is reduced with at least two NRS points or 30% from baseline - that dose is administered for two hours continuously. Following treatment the patient will be observed for an hour before leaving the hospital or recovery unit, again, all according to current daily clinical practice.
Study: NCT05598450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS and MEG for auditory hallucinations via self controlled clinical trials
Description: a 4 weeks, weekly 345（23min\*3times\*5day） minutes, 1Hz, 100%RMT-rTMS protocol~Detail precedure:~Before intervention, each patient was scheduled to collect three magnetoencephalogram data sessions. Apply MEG technology to calculate possible locations and determine three intervention targets. Pseudo stimulation in the first week, 5-day intervention, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. Evaluate the scale after the first week of pseudo stimulation. Week 2-4 real stimulation, intervention 5 days a week, 3 targets per day, each target for 23 minutes, with a 30 minute interval between each target. After the end of the fourth week, evaluate the scale. And follow-up evaluations will be conducted on the 7th, 14th, 30th, 60th, and 90th days after the intervention.
Study: NCT06578598

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Igelplus
Description: Intubation with Igelplus laryngeal mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Igelplus
Description: Intubation with Igelplus laryngeal mask
Study: NCT05899283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCI-HF160
Description: OCI-HF160 are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCI-HF160
Description: OCI-HF160 are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX800HDF
Description: FX800HDF are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
Study: NCT05044078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic Inhibition MET
Description: If a sub-maximal contraction of the muscle is followed by stretching of the same muscle it is known as Autogenic Inhibition MET.
Study: NCT05899283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FX800HDF
Description: FX800HDF are used in patients for hemofiltration, hemodialysis and hemodiafiltration, to correct solute and fluid imbalances in patients' blood.
Study: NCT05142631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: To observe the efficacy and safety of Fruquintinib in the first-line treatment of desmoplastic small round cell tumor, epithelioid hemangioendothelioma, solitary fibroma or second-line and posterior line treatment of angiosarcoma.
Study: NCT05576272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 5 mg/kg#D1#Q3W IV, 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carrelizumab
Description: 200mg#D1#Q3W IV, 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1000mg/m2#D1\&D8#Q3W IV, 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2#D1\&D8#Q3W IV, 4-6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 80mg/m2#D1#Q3W IV, 4-6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80mg/m2#D1#Q3W IV, 4-6 cycles
Study: NCT05044078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reciprocal Inhibition MET
Description: If a submaximal contraction of a muscle is followed by stretching of the opposite muscle then this is known as Reciprocal Inhibition MET.
Study: NCT05106816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin surface vibration
Description: This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin surface vibration
Description: This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: light skin surface vibration- SHAM
Description: This study will use four vibrating devices worn on each of the limbs. The devices are paired with a cell phone application (to be used solely by research investigators) that adjusts the vibration settings. The intensity of the vibration produced by the device is far less than that produced by commercially available massagers used for relaxation using similar technology. The sensor in the device is a tri-axial accelerometer and gyroscope that measures position using the same technology as smartphones. Worn at the lowest frequency will simulate the active arms with no potential change in symptoms.
Study: NCT05353842

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WOWii Program
Description: Workout on Wheels Internet Internvention (WOWii) which includes: 1) WOWii website to guide participants in an exercise program, 2) home exercise starter program; 3) weekly support from a peer facilitator via online (video) meetings.
Study: NCT05411783

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tie of IMV
Description: The IMV will be tie under the left colic vein
Study: NCT05549713

Intervention type: PROCEDURE
Intervention: Upper blepharoplasty
Description: Upper eyelid surgery in local anesthesia performed by removing excess skin folds and closing with sutures placed on the skin crease.
Study: NCT05294016

Intervention type: DEVICE
Group type: OTHER
Intervention: BRA CONNECT device
Description: skin thermal analysis for the detection of breast abnormalities

Intervention type: DEVICE
Group type: OTHER
Intervention: BRA CONNECT device
Description: skin thermal analysis for the detection of breast abnormalities
Study: NCT04927741

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sweet Marjoram Essential Oil
Description: Subjects will receive a dilution of sweet marjoram essential oil (15 cc of grapeseed oil with 10 drops of sweet marjoram essential oil).~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Grapeseed Oil
Description: Subjects will receive 15 cc of undiluted grapeseed oil.~Oil will be applied topically by the study medical providers. Providers will wear exam gloves, dip three fingers into the oil solution and apply it topically to the subject's lower abdomen. This will be applied by going left to right for 20 seconds while applying gentle pressure - counter pressure may be applied on the uterus to help relieve cramping.
Study: NCT04324944

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Decision Skills Training
Description: An ten-session group-based skills training intervention that focuses on treatment-related decision-making in order to facilitate improved engagement in decision-making processes. CDST teaches assertiveness skills, problem solving, goal planning, and conflict negotiation, within the context of treatment planning and decision-making. Each session is 60 minutes long.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leveling Up
Description: An ten-session group intervention that focuses on psychoeducation around befriending. Each session is 60 minutes long.
Study: NCT05429125

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Tube with Stylet
Description: Patients randomised to Endotracheal Tube with Stylet will be intubated with a Videolaryngoscopy and with an endotracheal tube + stylet.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Tip Bougie
Description: Patients randomised to Flexible Tip Bougie will be intubated with a Videolaryngoscopy and with a Flexible Tip Bougie.
Study: NCT05800665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7656594
Description: RO7656594 will be administered orally at specified dose on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7656594
Description: RO7656594 will be administered orally at specified dose on specified days.
Study: NCT06095128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab IV infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: Tofacitinib Tablets
Study: NCT06538675

Intervention type: OTHER
Intervention: Psychotherapy
Description: Patients are assigned to a therapist and will receive psychotherapy

Intervention type: OTHER
Intervention: Psychotherapy
Description: Patients are assigned to a therapist and will receive psychotherapy

Intervention type: OTHER
Intervention: Psychotherapy
Description: Patients are assigned to a therapist and will receive psychotherapy

Intervention type: OTHER
Intervention: Psychotherapy
Description: Patients are assigned to a therapist and will receive psychotherapy
Study: NCT05856786

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography
Description: Posterior segment OCT (a non-contact procedure performed over one minute) is additionally performed for patients participating in this study. Proportion of change in measurements in microns will be analyzed.
Study: NCT03921515

Intervention type: OTHER
Group type: OTHER
Intervention: Blister induction
Description: Blister induction involves creating 8 blisters on the forearm and removing the tops of the blisters for primary cell culture derivation. After blister induction, subjects may have an optional overnight admission to assess cell infiltration in response to autologous serum and/or sterile saline solution.

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Biopsies
Description: The skin biopsies will involve up to 4 biopsies: 2 initial punch biopsies 2 mm in diameter, followed by a punch biopsy 3 (plus or minus 1) and 7 (plus or minus 2) days later using a 3 mm punch to encompass the initial biopsy sites, capturing the tissue at 3 and 7 days of healing.
Study: NCT06643390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2225
Description: Subcutaneous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous administration
Study: NCT05750953

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth@Hospital-2-Home
Description: At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company. MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals. The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices. Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
Study: NCT06636526

Intervention type: GENETIC
Intervention: The i4i PRODICT™ test.
Description: The i4i PRODICT™ test combining both common and rare genetic variants into one saliva-based DNA test to estimate a person's future risk of prostate cancer. This test will be offered to all participants in Part 1 of the study. Participants will be classified into high-risk or population risk based on the results of the i4i PRODICT™ test. Those classified as high-risk due to either falling within the high polygenic risk score category, and/or having a rare variant in a gene in the test will be offered targeted prostate cancer screening.
Study: NCT05217134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DPEA
Description: Dural puncture with 27 G Whitacre needle